Skip to main content

Advertisement

Table 4 Logistic regression models for pCR with p values, odds ratio, and confidence intervals

From: Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

miRNAs Patients All BC patients HER2-positive patients TNBC patients
Model Univariate Multivariate Univariate Multivariate Univariate Multivariate
miR-20a All _ _ _ _ _ _
In PM _ _ _ _ _ _
In PMCb p = 0.020
1.39 (1.05–1.84)
p = 0.019
1.41 (1.06–1.89)
_ _ _ _
miR-27b All _ _ p = 0.035
1.30 (1.02–1.65)
p = 0.050
1.28 (1.00–1.63)
_ _
In PM _ _ _ _ _ _
In PMCb p = 0.038
1.27 (1.01–1.59)
p = 0.030
1.30 (1.03–1.64)
_ _ _ _
miR-99b All p = 0.103
1.14 (0.97–1.34)
p = 0.039
1.19 (1.01–1.41)
_ _ _ _
In PM _ _ _ _ _ _
in PMCb _ _ _ _ _ _
miR-155 All p = 0.002
1.25 (1.08–1.44)
p = 0.003
1.24 (1.08–1.44)
p = 0.049
1.24 (1.00–1.53)
p = 0.035
1.26 (1.02–1.56)
p = 0.013
1.29 (1.05–1.57)
p = 0.018
1.29 (1.04–1.58)
In PM p = 0.033
1.26 (1.02–1.55)
p = 0.049
1.24 (1.00–1.53)
_ _ _ _
In PMCb p = 0.032
1.24 (1.02–1.51)
p = 0.023
1.27 (1.03–1.55)
_ _ _ _
miR-193b All p = 0.039
1.13 (1.01–1.26)
p = 0.055
1.12 (1.00–1.26)
p = 0.010
1.26 (1.06–1.50)
p = 0.012
1.26 (1.05–1.51)
_ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-301 All p = 0.002
1.25 (1.08–1.44)
p = 0.001
1.27 (1.10–1.46)
p = 0.013
1.30 (1.06–1.60)
p = 0.011
1.32 (1.07–1.64)
_ _
In PM p = 0.040
1.22 (1.01–1.48)
p = 0.028
1.25 (1.02–1.52)
_ _ _ _
In PMCb p = 0.020
1.28 (1.04–1.57)
p = 0.022
1.29 (1.04–1.6)
p = 0.012
1.53 (1.10–2.12)
p = 0.016
1.51 (1.08–2..12)
_ _
miR-365 All _ _ _ _ _ _
In PM _ _ p = 0.052
1.35 (1.00–1.81)
p = 0.038
1.39 (1.02–1.90)
_ _
In PMCb _ _ _ _ _ _
miR-423-5p All p = 0.048
1.19 (1.00–1.42)
p = 0.064
1.18 (0.99–1.41)
_ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-511 All _ _ _ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ p = 0.239
0.90 (0.76–1.07)
p = 0.043
0.78 (0.62–0.99)
miR-628-5p All _ _ _ _ p = 0.024
0.81 (0.67–0.97)
p = 0.017
0.79 (0.65–0.96)
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-660 All _ _ p = 0.044
1.35 (1.01–1.80)
p = 0.027
1.40 (1.04–1.89)
_ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-891a All p = 0.063
1.07 (1.00–1.15)
p = 0.036
1.08 (1.01–1.16)
_ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
  1. Cells filled with “-” denote insignificant miRNA contributions to the models. MiRNAs which do not show significant contributions in any population were omitted. For each miRNA variable and each patient group, a univariate as well as a multivariate model with the covariables of age, nodal status, tumor size, and grading were calculated
  2. The odds ratio with the 95% confidence interval and the associated Wald p value for the miRNAs are presented
  3. PM non-carboplatin treatment arm, PMCb carboplatin treatment arm